Syapse to utilize NCCN Biomarkers Compendium for clinical care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Comprehensive Cancer Network and Syapse announced an agreement w to expand the use of best practices in precision medicine.

Syapse delivers solutions for scaling enterprise precision oncology programs. The data contained in the NCCN Biomarkers Compendium will strengthen Syapse’s decision support and workflow tools, increasing access to more personalized care.

The NCCN Biomarkers Compendium is part of NCCN’s Library of Compendia, which also includes databases for Drugs & Biologics (NCCN Compendium), as well as the NCCN Radiation Therapy Compendium, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC).

The NCCN-supported data will begin appearing on the Syapse platform in late 2018. Syapse is committed to updating that content weekly to keep pace with the NCCN Guidelines.

Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login